The treatment landscape for patients with both resectable and non-resectable non-small cell lung cancer (NSCLC) is undergoing a transformative shift due to the promising results arising from several clinical trials. The treatment landscape of the resectable setting is certainly more dynamic than that of the non-resectable setting where durvalumab is the only available immunotherapy option. Here, an overview of the treatment strategies for both resectable and non-resectable NSCLC will be discussed.
